Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 18/20 | 0.52 |
| ▸ | ESR1 | P03372 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29097441 | 0.80 | ALDH1A1 (0.41) | — | |
| SCHEMBL780217 | 0.79 | SLC18A3 (0.43) | CYP2D6 | |
| SCHEMBL5704310 | 0.79 | ESR2 (0.61) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL56284 | 0.78 | ESR2 (0.69) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2094843 | 0.78 | ESR2 (0.76) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL11871181 | 0.76 | ESR2 (0.80) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL699003 | 0.76 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL698472 | 0.76 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL698289 | 0.76 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL28569320 | 0.76 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158428-A1 | Intermediates and processes for preparing substituted chromanol derivatives | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| WO-2002060888-A1 | PROCESSES FOR PREPARING CHROMANYLBENZOIC ACIDS | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158428-A1 | Intermediates and processes for preparing substituted chromanol derivatives | CYP1A1, CYP2F1, CYP7A1 | ESR2 497/4885ESR1 392/4885CYP3A4 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.